| 0.1302 0.001 (0.93%) | 04-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.32 | 1-year : | 0.44 |
| Resists | First : | 0.27 | Second : | 0.37 |
| Pivot price | 0.14  |
|||
| Supports | First : | 0.11 | Second : | 0.09 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.15 |
| MA(100) : | 0.37 |
MA(250) : | 0.68 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19 |
D(3) : | 10.8 |
| RSI | RSI(14): 24.8 |
|||
| 52-week | High : | 1.52 | Low : | 0.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NLSP ] has closed above bottom band by 17.5%. Bollinger Bands are 76.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.14 - 0.14 | 0.14 - 0.14 |
| Low: | 0.11 - 0.12 | 0.12 - 0.12 |
| Close: | 0.13 - 0.13 | 0.13 - 0.13 |
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Fri, 19 Apr 2024
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing - Yahoo Finance
Fri, 22 Mar 2024
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering - Yahoo Finance
Wed, 20 Mar 2024
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering - Yahoo Finance
Wed, 20 Mar 2024
NLS Pharmaceutics launches $1.75M share and warrant offering - Investing.com
Wed, 20 Mar 2024
NLS Pharmaceutics Extends Loan Maturity Date - TipRanks.com - TipRanks
Fri, 23 Feb 2024
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 31.5 (%) |
| Held by Institutions | 23.8 (%) |
| Shares Short | 336 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -414.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.27 |
| PEG Ratio | 0 |
| Price to Book value | -1.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|